Výsledky vyhledávání - "Sarah E. Wong"

Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer

Autor: Louis Everest, Sarah E. Wong, Di Maria Jiang, Srikala S. Sridhar, Kelvin K. W. Chan, Ronak Saluja

Publikováno v: JCO Oncology Practice. 16:e201-e210

PURPOSE: As novel hormonal therapies, such as abiraterone and enzalutamide, move into earlier stages of treatment of advanced prostate cancer, there are significant cost implications. We used the ASCO Value Framework (AVF) and European Society of Med

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c77d59c54d9237fc1f0821fcc1395b21
https://doi.org/10.1200/jop.19.00421

Zobrazit plný text záznamu

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies

Autor: Srikala S. Sridhar, Scott North, Christopher Sweeney, Sarah E. Wong, Martin R. Stockler

Publikováno v: Clinical genitourinary cancer.

Background Screen failures, defined as individuals who undergo screening but are not enrolled in a clinical trial, incur significant costs without contributing valuable data to the study. Despite these costs, there are few published data about the ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb614b380139b4358cb8c2979d12e27c
https://pubmed.ncbi.nlm.nih.gov/28993132

Zobrazit plný text záznamu

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Autor: Damien Thomson, Paul Vasey, Nimit Singhal, Craig R. Lewis, Michael Friedlander, Martin R. Stockler, M. Rosenthal, Sarah E. Wong, Ganessan Kichenadasse, Peter Grimison, Howard Gurney, Nicola Jane Lawrence, Annie Yeung, Guy C. Toner, Luke Buizen, Val Gebski, Nicole Wong, Andrew J. Martin

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 27(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f414e272e9a2216f55d204b2ad4a3579
https://pubmed.ncbi.nlm.nih.gov/27502724

Zobrazit plný text záznamu

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Autor: Martin R. Stockler, Peter Grimison, Paul Vasey, Mark Rosenthal, Michael Friedlander, Mark D. Chatfield, Guy C. Toner, Amy L. Boland, Val Gebski, Howard Gurney, Baerin Houghton, Craig R. Lewis, Damien Thomson, Sarah E. Wong, Ganessan Kichenadasse, N. Singhal

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 25(1)

Background This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerability and activity of accelerated bleomycin, etoposide and cisplatin (BEP) as first-line chemotherapy for metastatic germ cell tumours. Patients and meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7ae88ab3e4cddabf2f9eabf815b1fe
https://pubmed.ncbi.nlm.nih.gov/24356618

Zobrazit plný text záznamu

Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies

Autor: Scott North, Martin R. Stockler, Christopher Sweeney, Sarah E. Wong, Srikala S. Sridhar

Publikováno v: Journal of Clinical Oncology. 34:176-176

176 Background: Screen failures cost effort, time and resources estimated at about $2000 per patient (Bienkowski RS et al 2008). There is little published data about the frequency or causes of screen failures in genitourinary (GU) cancer clinical tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::213b2a1910432a87f8309f4918fbdafc
https://doi.org/10.1200/jco.2016.34.2_suppl.176

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání